Kirby McInerney LLP Alerts Investors Who Acquired Unicycive Therapeutics, Inc. UNCY Securities Between December 29, 2025 and June 29, 2026 of Pending Lawsuit

A securities class action lawsuit has been filed against Unicycive Therapeutics for allegedly making false statements about its manufacturing vendor's FDA compliance. The company failed to disclose that it had not inspected the third-party facility or audited its compliance with manufacturing practices. On June 30, 2026, the FDA issued a second Complete Response Letter citing the same manufacturing deficiencies, causing Unicycive's stock to plummet 39.1% to $4.69 per share. The lead plaintiff deadline is November 2, 2026.